NanoViricides Inc. - NNVC STOCK NEWS

NanoViricides (NYSE:NNVC) has engaged a Clinical Research Organization to conduct a Phase II clinical trial for its broad-spectrum antiviral drug NV-387, focusing on MPox treatment. The development comes as MPox disease caused a regional pandemic in African countries, leading to WHO declaring a Public Health Emergency in August 2024.

NV-387 has demonstrated strong antiviral activity against orthopoxviruses, matching the effectiveness of tecovirimat in both skin and lung infection models. Unlike tecovirimat, which failed its clinical trial, NV-387's host-mimetic mechanism makes viral escape highly unlikely. The drug has shown promising results in treating RSV and was found superior to existing treatments in influenza models.

NanoViricides (NYSE American:NNVC) announced its upcoming presentation at Biotech Showcase™ 2025 in San Francisco on Tuesday, January 14, 2025, at 2:30pm PT. The presentation will be held at the Hilton San Francisco - Union Square.

The company will showcase its Phase II-ready drug NV-387, which has demonstrated broad-spectrum antiviral activity. NV-387 has shown superior effectiveness compared to existing treatments like Tamiflu®, Rapivab®, and Xofluza® in treating Influenza A. The drug has also demonstrated promising results against MPox, Smallpox, RSV, and SARS-CoV-2 infections in animal models.

NV-387's unique mechanism mimics a host-side feature used by 90-95% of human pathogenic viruses, making it difficult for viruses to develop resistance. The overall market size for NV-387 indications is estimated to exceed $10 billion. The company has also developed a platform enabling non-oral drugs to be delivered as active oral drugs.

NanoViricides (NYSE: NNVC) discusses multiple viral threats and their lead drug candidate NV-387. The company highlights concerns about two H5N1 bird flu genotypes: the severe D1.1 form and the less severe B3.13 variant affecting dairy cattle. The first U.S. H5N1 fatality was reported on January 6, 2025, in Louisiana.

NV-387 has shown superior activity compared to existing treatments in animal models against multiple viruses, including Influenza A H3N2, coronavirus, orthopoxvirus, and RSV. The drug's broad-spectrum capability and unique mechanism targeting host-side features make viral escape unlikely, even as viruses evolve.

The company emphasizes that current seasonal outbreaks of COVID-19, RSV, hMPV, and Norovirus, along with emerging H5N1 mutations that can escape vaccines and antibodies, demonstrate the need for broad-spectrum antivirals like NV-387.

NanoViricides (NYSE:NNVC) announces its broad-spectrum antiviral drug candidate NV-387 as a potential solution against H5N1 bird flu pandemic. The company claims the virus is unlikely to develop resistance to NV-387 as it mimics essential host-side features that H5N1 continues to use despite mutations.

In animal studies, NV-387 demonstrated 88% increased survival compared to existing treatments like oseltamivir (25%), peramivir (38%), and baloxivir (38%). The drug has completed Phase I clinical trials with no adverse events and is preparing for Phase II trials for MPox treatment and respiratory virus infections.

The WHO has noted that current H5N1 strains show reduced susceptibility to existing treatments (NAIs and PBIs), highlighting the need for more effective solutions. While the US has stockpiled H5N1 vaccines, their effectiveness against potential pandemic strains remains uncertain.

NanoViricides (NYSE:NNVC) reported Q3 2024 financial results with cash and equivalents of $3.87 Million and net property assets of $7.36 Million. The company's lead drug candidate NV-387, a broad-spectrum antiviral, is progressing toward Phase II clinical trials for multiple indications including MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71 million through ATM offering and has access to a $3 million credit line, though additional funding will be needed for planned Phase II trials. NV-387 has shown promising results in animal trials, potentially offering superior effectiveness compared to existing treatments for various viral infections.

NanoViricides (NYSE:NNVC) announces a corporate presentation at the Spartan Capital Investors Conference 2024 on November 4, featuring their lead drug candidate NV-387. The presentation will highlight NV-387's completion of Phase I clinical trials and its demonstrated antiviral activity against multiple viruses including Influenza, RSV, COVID, and MPox/Smallpox. The company notes that NV-387 targets a market estimated at $2.5 to $4.3 billion for RSV alone, with the overall market for targeted indications projected to exceed $10 billion by 2027.

NanoViricides announces that Dr. Anil R. Diwan, President and Executive Chairman, will present at the PODD Conference on October 28, 2024, at 3:45 PM. The conference will take place at the Westin Boston Seaport District, MA. Dr. Diwan's talk, titled 'Revolutionizing Antiviral Treatments, Phase 2-Ready, Orally Available Nanomedicines That Can Deliver Difficult APIs And Improve PK', will focus on the nanoviricides platform technology and its achievements.

Key points include the broad-spectrum drug candidate NV-387, which has completed Phase 1 trials with excellent safety and efficacy against various viruses, including RSV, Influenza A/H3N2, coronavirus, and poxvirus. NV-387 is orally available and has shown superior results compared to existing treatments like oseltamivir, peramivir, and remdesivir in animal models. Dr. Diwan will also discuss the platform's potential to revolutionize drug delivery, enabling oral availability and protection from metabolism for difficult drugs.

NanoViricides, Inc. (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, was interviewed in a PODD Conference podcast. Dr. Diwan discussed the company's nanoviricides technology platform and its broad-spectrum antiviral clinical drug candidate NV-387. He explained how NV-387 could revolutionize viral infection treatment, similar to penicillin's impact on bacterial infections.

Dr. Diwan highlighted NV-387's potential to resist viral escape and the company's multiple Phase II clinical trial strategies. He also elaborated on how the nanoviricide platform can aid other pharmaceutical innovators in developing effective drugs. The technology enables oral drug delivery of difficult-to-dose APIs, protects APIs from bodily metabolism, and allows for targeted drug delivery to specific cells or pathogens.

NanoViricides (NYSE American:NNVC) announces that its President, Dr. Anil R. Diwan, will present at the Global AMR Summit 2024 on October 9, 2024, in Cambridge, MA. Dr. Diwan will discuss the company's 'Trojan Horse' Platform Technology to combat antimicrobial resistance (AMR).

The technology enables delivery of 'war-heads' directly onto pathogens, potentially reducing toxicity and improving pharmacokinetics. NanoViricides' lead drug, NV-387, has completed Phase 1a/1b trials with no reported adverse events. It has shown strong antiviral activity against multiple virus families, including Coronaviruses, RSV, and Influenza A.

NV-387 could be the first single drug to treat all 'tripledemic' viral infections. The company is also developing 'dual-action' nanoviricides to potentially cure viral infections by blocking the complete Virus Life Cycle.